과제정보
This research was funded by the Margaret Elcombe Research Fellowship, The Hospital Research Foundation.
참고문헌
- Nakhjavani M, Hardingham JE, Palethorpe HM, Tomita Y, Smith E, Price TJ, et al. Ginsenoside Rg3: potential molecular targets and therapeutic indication in metastatic breast cancer. Medicines 2019;6(1):17.
- Nakhjavani M, Smith E, Townsend AR, Price TJ, Hardingham JE. Anti-angiogenic properties of ginsenoside Rg3. Molecules 2020;25(21):4905.
- Pan L, Zhang T, Sun H, Liu G. Ginsenoside Rg3 (shenyi capsule) combined with chemotherapy for digestive system cancer in China: a meta-analysis and systematic review. Evid Based Complement Alternat Med 2019;2019:2417418.
- Lu P, Su W, Miao ZH, Niu HR, Liu J, Hua QL. Effect and mechanism of ginsenoside Rg3 on postoperative life span of patients with non-small cell lung cancer. Chin J Integr Med 2008;14(1):33-6. https://doi.org/10.1007/s11655-007-9002-6
- Zhou B, Yan Z, Liu R, Shi P, Qian S, Qu X, et al. Prospective study of transcatheter arterial chemoembolization (TACE) with ginsenoside Rg3 versus TACE alone for the treatment of patients with advanced hepatocellular carcinoma. Radiology 2016;280(2):630-9. https://doi.org/10.1148/radiol.2016150719
- Li Y, Wang Y, Niu K, Chen X, Xia L, Lu D, et al. Clinical benefit from EGFR-TKI plus ginsenoside Rg3 in patients with advanced non-small cell lung cancer harboring EGFR active mutation. Oncotarget 2016;7(43):70535-45. https://doi.org/10.18632/oncotarget.12059
- Xie HT, Wang GJ, Sun JG, Tucker I, Zhao XC, Xie YY, et al. High performance liquid chromatographic-mass spectrometric determination of ginsenoside Rg3 and its metabolites in rat plasma using solid-phase extraction for pharmacokinetic studies. J Chromatogr B Analyt Technol Biomed Life Sci 2005;818(2):67-73. https://doi.org/10.1016/j.jchromb.2004.09.059
- Peng M, Li X, Zhang T, Ding Y, Yi Y, Le J, et al. Stereoselective pharmacokinetic and metabolism studies of 20(S)- and 20(R)-ginsenoside Rg3 epimers in rat plasma by liquid chromatography-electrospray ionization mass spectrometry. J Pharm Biomed Anal 2016;121:215-24. https://doi.org/10.1016/j.jpba.2016.01.020
- Nakhjavani M, Palethorpe HM, Tomita Y, Smith E, Price TJ, Yool AJ, et al. Stereoselective anti-cancer activities of ginsenoside Rg3 on triple negative breast cancer cell models. Pharmaceuticals 2019;12(3):117.
- Nakhjavani M, Smith E, Yeo K, Palethorpe HM, Tomita Y, Price TJ, et al. Antiangiogenic properties of ginsenoside Rg3 epimers: in vitro assessment of single and combination treatments. Cancers 2021;13(9):2223.
- De Ieso ML, Yool AJ. Mechanisms of aquaporin-facilitated cancer invasion and metastasis. Front Chem 2018;6:135.
- Smith E, Palethorpe HM, Tomita Y, Pei JV, Townsend AR, Price TJ, et al. The purified extract from the medicinal plant bacopa monnieri, bacopaside II, inhibits growth of colon cancer cells in vitro by inducing cell cycle arrest and apoptosis. Cells 2018;7(7):81.
- Paltoglou S, Das R, Townley SL, Hickey TE, Tarulli GA, Coutinho I, et al. Novel androgen receptor coregulator GRHL2 exerts both oncogenic and antimetastatic functions in prostate cancer. Cancer Res 2017;77(13):3417-30. https://doi.org/10.1158/0008-5472.CAN-16-1616
- Tomita Y, Palethorpe HM, Smith E, Nakhjavani M, Townsend AR, Price TJ, et al. Bumetanide-derived aquaporin 1 inhibitors, AqB013 and AqB050 inhibit tube formation of endothelial cells through induction of apoptosis and impaired migration in vitro. Int J Mol Sci 2019;20(8):1818.
- Palethorpe HM, Smith E, Tomita Y, Nakhjavani M, Yool AJ, Price TJ, et al. Bacopasides I and II act in synergy to inhibit the growth, migration and invasion of breast cancer cell lines. Molecules 2019;24(19):3539.
- Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem 2003;373(1):65-70. https://doi.org/10.1042/bj20030341
- Zinonos I, Labrinidis A, Liapis V, Hay S, Panagopoulos V, Denichilo M, et al. Doxorubicin overcomes resistance to drozitumab by antagonizing Inhibitor of Apoptosis Proteins (IAPs). Anticancer Res 2014;34(12):7007-20.
- PubChem. PubChem compound summary for CID 119307. Ginsenoside Rh2. NCBI [Internet]. 2020 Nov [cited 2020 Nov 11]. 2020. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/Ginsenoside-Rh2.
- PubChem. PubChem compound summary for CID 11213350 (20S)-Protopanaxadiol. NCBI [Internet]. 2020 Nov [cited 2020 Nov 11]. 2020. Available from: https://pubchem.ncbi.nlm.nih.gov/compound/20S_-Protopanaxadiol.
- Pei JV, Kourghi M, De Ieso ML, Campbell EM, Dorward HS, Hardingham JE, et al. Differential inhibition of water and ion channel activities of mammalian aquaporin-1 by two structurally related bacopaside compounds derived from the medicinal plant bacopa monnieri. Mol Pharmacol 2016;90(4):496-507. https://doi.org/10.1124/mol.116.105882
- Zhu S, Liu X, Xue M, Li Y, Cai D, Wang S, et al. 20(S)-ginsenoside Rh2 induces caspase-dependent promyelocytic leukemia-retinoic acid receptor A degradation in NB4 cells via Akt/Bax/caspase9 and TNF-α/caspase8 signaling cascades. J Ginseng Res 2020;45(2):295-304. https://doi.org/10.1016/j.jgr.2020.05.001
- Xia T, Zhang J, Zhou C, Li Y, Duan W, Zhang B, et al. 20(S)-Ginsenoside Rh2 displays efficacy against T-cell acute lymphoblastic leukemia through the PI3K/Akt/mTOR signal pathway. J Ginseng Res 2020;44(5):725-37. https://doi.org/10.1016/j.jgr.2019.07.003
- Yang J, Yuan D, Xing T, Su H, Zhang S, Wen J, et al. Ginsenoside Rh2 inhibiting HCT116 colon cancer cell proliferation through blocking PDZ-binding kinase/T-LAK cell-originated protein kinase. J Ginseng Res 2016;40(4):400-8. https://doi.org/10.1016/j.jgr.2016.03.007
- Liu J, Shimizu K, Yu H, Zhang C, Jin F, Kondo R. Stereospecificity of hydroxyl group at C-20 in antiproliferative action of ginsenoside Rh2 on prostate cancer cells. Fitoterapia 2010;81(7):902-5. https://doi.org/10.1016/j.fitote.2010.05.020
- Usami Y, Liu Y-N, Lin A-S, Shibano M, Akiyama T, Itokawa H, et al. Antitumor agents. 261. 20 (S)-protopanaxadiol and 20 (S)-protopanaxatriol as antiangiogenic agents and total assignment of 1H NMR spectra. J Nat Prod 2008;71(3):478-81. https://doi.org/10.1021/np070613q
- Choi S, Kim TW, Singh SV. Ginsenoside Rh2-mediated G1 phase cell cycle arrest in human breast cancer cells is caused by p15 Ink4B and p27 Kip1-dependent inhibition of cyclin-dependent kinases. Pharm Res 2009;26(10):2280-8. https://doi.org/10.1007/s11095-009-9944-9
- Snyder AG, Hubbard NW, Messmer MN, Kofman SB, Hagan CE, Orozco SL, et al. Intratumoral activation of the necroptotic pathway components RIPK1 and RIPK3 potentiates antitumor immunity. Sci Immunol 2019;4(36).
- Shlomovitz I, Speir M, Gerlic M. Flipping the dogma-phosphatidylserine in non-apoptotic cell death. Cell Commun Signal 2019;17(1):1-12. https://doi.org/10.1186/s12964-018-0315-1
- Pietkiewicz S, Schmidt JH, Lavrik IN. Quantification of apoptosis and necroptosis at the single cell level by a combination of Imaging Flow Cytometry with classical Annexin V/propidium iodide staining. J Immunol Methods 2015;423:99-103. https://doi.org/10.1016/j.jim.2015.04.025
- Su Z, Yang Z, Xu Y, Chen Y, Yu Q. Apoptosis, autophagy, necroptosis, and cancer metastasis. Mol Cancer 2015;14(1):48.
- Gong Y, Fan Z, Luo G, Yang C, Huang Q, Fan K, et al. The role of necroptosis in cancer biology and therapy. Mol Cancer 2019;18(1):1-17. https://doi.org/10.1186/s12943-019-1029-8
- Han W, Li L, Qiu S, Lu Q, Pan Q, Gu Y, et al. Shikonin circumvents cancer drug resistance by induction of a necroptotic death. Mol Cancer Ther 2007;6(5):1641-9. https://doi.org/10.1158/1535-7163.MCT-06-0511
- Xuan Y, Hu X. Naturally-occurring shikonin analogues-a class of necroptotic inducers that circumvent cancer drug resistance. Cancer Lett 2009;274(2):233-42. https://doi.org/10.1016/j.canlet.2008.09.029
- Fu Z, Deng B, Liao Y, Shan L, Yin F, Wang Z, et al. The anti-tumor effect of shikonin on osteosarcoma by inducing RIP1 and RIP3 dependent necroptosis. BMC Cancer 2013;13(1):1-10. https://doi.org/10.1186/1471-2407-13-1
- Wang X, Xia HY, Qin HY, Kang XP, Hu HY, Zheng J, et al. 20 (S)-protopanaxadiol induces apoptosis in human umbilical vein endothelial cells by activating the PERK-eIF2alpha-ATF4 signaling pathway. J Cell Biochem 2019;120(4):5085-96. https://doi.org/10.1002/jcb.27785
- Zhang XP, Li KR, Yu Q, Yao MD, Ge HM, Li XM, et al. Ginsenoside Rh2 inhibits vascular endothelial growth factor-induced corneal neovascularization. FASEB J 2018;32(7):3782-91. https://doi.org/10.1096/fj.201701074RR
- Tomita Y, Dorward H, Yool AJ, Smith E, Townsend AR, Price TJ, et al. Role of aquaporin 1 signalling in cancer development and progression. Int J Mol Sci 2017;18(2):299.
- Brozzo MS, Bjeliꠑc S, Kisko K, Schleier T, Leppanen V-M, Alitalo K, et al. Thermodynamic and structural description of allosterically regulated VEGFR-2 dimerization. Blood 2012;119(7):1781-8. https://doi.org/10.1182/blood-2011-11-390922
- Christensen J. A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 2007;18:x3-10. https://doi.org/10.1093/annonc/mdm408
- De Smet F, Christopoulos A, Carmeliet P. Allosteric targeting of receptor tyrosine kinases. Nat Biotechnol 2014;32(11):1113-20. https://doi.org/10.1038/nbt.3028
- Yool AJ, Brown EA, Flynn GA. Roles for novel pharmacological blockers of aquaporins in the treatment of brain oedema and cancer. Clin Exp Pharmacol Physiol 2010;37(4):403-9. https://doi.org/10.1111/j.1440-1681.2009.05244.x